2016 HFSA Board Review Course:  
Advanced Heart Failure and Transplant Cardiology

HFSA Board Review Course Content is based on the ABIM content blueprint for the certification examination in Advanced Heart Failure and Transplant Cardiology. The following areas are addressed:

- Epidemiology and Causes of Heart Failure
- Pathophysiology of Heart Failure
- Evaluation of Heart Failure
- Management of Hospitalized Patients
- Management of Heart Failure
- Comorbidities or Coexisting Conditions
- Cardiac Surgery in Heart Failure
- Heart Transplant
- Mechanical Circulatory Support
- Pulmonary Arterial Hypertension
- Contemporary HF Management Topics

Concise presentations by national experts will be augmented by board-review-type questions using an audience-response system.

Date of Release: November 1, 2016  
Program End Date: October 31, 2018

Target Audience:  
Cardiologists, internists, nurses, clinical pharmacists, and other health professionals with a special interest in heart failure.

Program Objectives:  
Upon completing this educational activity, participants will be able to:

1. Describe the epidemiology of heart failure, including environmental factors, and implement strategies for the prevention of heart failure.
2. Describe the pathophysiology of heart failure, including normal physiology and compensatory and maladaptive mechanisms at the structural, neurohormonal, and cellular levels.
3. Assess and follow the patient with advanced heart failure, using non-invasive and invasive tests and biomarkers.
4. Implement guideline-based therapy for patients with advanced heart failure, including pharmacologic agents; non-pharmacologic options, such as diet and exercise; and devices.
5. Manage comorbidities in patients with advanced heart failure, including hypertension, diabetes, and cognitive issues.
6. Implement strategies for effective disease management of the patient with advanced heart failure, including end-of-life issues.
7. Provide peri-operative management of heart failure patients undergoing non-cardiac surgery, cardiac transplantation, or implantation of a mechanical circulatory device.

**Accreditation Statements:**
The Heart Failure Society of America is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

**Designation Statement:**
The Heart Failure Society of America designates this enduring material for a maximum of 19.5 AMA PRA Category 1 Credits™.

Physicians should claim credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 19.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for granting ABIM MOC credit.

**Pre-Test:**
You are required to take the pre-test prior to viewing each of the sessions. You can only take the pre-test once. Your score will not impact your ability to claim CME credit. After viewing the session, click on the CE Information tab within the session to take the Post-test.

**Course Content and Faculty Listing:**

<table>
<thead>
<tr>
<th>DAY 1</th>
<th>Faculty</th>
</tr>
</thead>
<tbody>
<tr>
<td>Live ABIM Style Question Session</td>
<td>James C. Fang &amp; Sean P. Pinney</td>
</tr>
<tr>
<td>Heart Failure Epidemiology and Risk Factors</td>
<td>Barry H Greenberg</td>
</tr>
<tr>
<td>Pathophysiology I: Cellular and Energetic Considerations</td>
<td>Daniel Burkhoff</td>
</tr>
<tr>
<td>Pathophysiology II: Hemodynamic, Structural, and Neurohormonal Considerations</td>
<td>Daniel Burkhoff</td>
</tr>
<tr>
<td>Clinical Assessment I: Diagnosis, Comorbidities</td>
<td>Barry H Greenberg</td>
</tr>
<tr>
<td>Contemporary Topics - ARNIs and Ivabradine</td>
<td>Clyde W. Yancy</td>
</tr>
<tr>
<td>Clinical Assessment II: Functional Capacity, Prognosis</td>
<td>Barry H Greenberg</td>
</tr>
<tr>
<td>Hemodynamics in Heart Failure I</td>
<td>James C. Fang</td>
</tr>
<tr>
<td>Topic</td>
<td>Presenter</td>
</tr>
<tr>
<td>----------------------------------------------------------------------</td>
<td>-------------------</td>
</tr>
<tr>
<td>Hemodynamics in Heart Failure II</td>
<td>James C. Fang</td>
</tr>
<tr>
<td>Cardiomyopathies I: Ischemic and Valvular</td>
<td>Joseph G. Rogers</td>
</tr>
<tr>
<td>Cardiomyopathies III: HCM and Inherited</td>
<td>Akshay Desai</td>
</tr>
<tr>
<td>Cardiomyopathies IV: ARVD and Sarcoid</td>
<td>Anju Nohria</td>
</tr>
<tr>
<td>Q &amp;A</td>
<td>Faculty</td>
</tr>
</tbody>
</table>

**DAY 2**

<table>
<thead>
<tr>
<th>Topic</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>Live ABIM Style Question Session</td>
<td>James C. Fang &amp; Sean P. Pinney</td>
</tr>
<tr>
<td>Cardio-Oncology</td>
<td>Anju Nohria</td>
</tr>
<tr>
<td>Heart Transplantation: Overview and Patient Selection</td>
<td>James C. Fang</td>
</tr>
<tr>
<td>Immunology: The Basics, PRA, Sensitization, Crossmatch</td>
<td>Sean P. Pinney</td>
</tr>
<tr>
<td>Rejection: Cellular and Antibody Mediated</td>
<td>Sean P. Pinney</td>
</tr>
<tr>
<td>Managing Immunosuppression and Drugs</td>
<td>James C. Fang</td>
</tr>
<tr>
<td>Post-Transplant Management Issues</td>
<td>James C. Fang</td>
</tr>
<tr>
<td>MCS I: Cardiogenic Shock and Temporary Support Devices</td>
<td>Joseph G. Rogers</td>
</tr>
<tr>
<td>Working Lunch: Contemporary Topics - Ambulatory</td>
<td></td>
</tr>
<tr>
<td>Hemodynamic Monitoring</td>
<td>Akshay Desai</td>
</tr>
<tr>
<td>MCS II: Durable MCS Selection and Outcomes</td>
<td>Joseph G. Rogers</td>
</tr>
<tr>
<td>MCS III: Adverse Events and Patient Management</td>
<td>Joseph G. Rogers</td>
</tr>
<tr>
<td>Pulmonary Hypertension</td>
<td>Johnathan D. Rich</td>
</tr>
<tr>
<td>Pericarditis and Myocarditis</td>
<td>Barry A. Borlaug</td>
</tr>
<tr>
<td>HFpEF and Infiltrative Cardiomyopathies</td>
<td>Barry A. Borlaug</td>
</tr>
<tr>
<td>Disease Management and Palliative Care</td>
<td>Barry A. Borlaug</td>
</tr>
<tr>
<td>Biomarkers in Heart Failure</td>
<td>Kirkwood Adams</td>
</tr>
<tr>
<td>Landmark Heart Failure Trails</td>
<td>Allen Anderson</td>
</tr>
</tbody>
</table>

**DAY 3**

<table>
<thead>
<tr>
<th>Topic</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q &amp; A</td>
<td>James C. Fang &amp; Sean P. Pinney</td>
</tr>
<tr>
<td>Acute Decompensated Heart Failure I</td>
<td>Kirkwood Adams</td>
</tr>
<tr>
<td>Acute Decompensated Heart Failure II</td>
<td>Kirkwood Adams</td>
</tr>
<tr>
<td>Drug Therapy for Chronic Heart Failure I</td>
<td>Mark Drazner</td>
</tr>
<tr>
<td>Drug Therapy for Chronic Heart Failure II</td>
<td>Mark Drazner</td>
</tr>
<tr>
<td>Management of Arrhythmias in Heart Failure</td>
<td>Joshua M. Cooper</td>
</tr>
<tr>
<td>Device Therapy in Heart Failure</td>
<td>Joshua M. Cooper</td>
</tr>
</tbody>
</table>

**Disclaimer:**

The educational activity presented above may involve simulated case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient is intended or should be inferred. The content, views and opinions presented in this educational activity are those of the authors and do not necessarily reflect those of HFSA.
Faculty:

James C. Fang, MD, FACC, FAHA
(Chair)
Professor of Medicine
Chief, Division of Cardiovascular Medicine
Executive Director, Cardiovascular Service Line
University of Utah
Salt Lake City, UT

Sean P. Pinney, MD
(Chair)
Director, Heart Failure and Transplantation,
The Mount Sinai Health System
Director, Advanced HF and Transplantation Program
The Mount Sinai Hospital
New York, NY

Kirkwood Adams, MD
Associate Professor,
Department of Medicine – Cardiology
Department of Radiology
University of North Carolina
University of North Carolina at Chapel Hill
Chapel Hill, NC

Allen S. Anderson, MD, FACC, FAHA
Professor of Medicine
Medical Director, Center for Heart Failure
Bluhm Cardiovascular Institute
Northwestern Medicine
Chicago, IL

Barry A. Borlaug, MD
Associate Professor of Medicine, Cardiovascular Diseases
Director, Circulator Failure Research
Mayo Clinic
Rochester, MN

Daniel Burkhoff, MD, PhD
Adjunct Associate Professor of Medicine, Columbia University
New York, NY
Adjunct Clinical Professor of Internal Medicine, The Ohio State University Medical Center
Columbus, OH
Joshua M. Cooper, MD
Director, Cardiac Electrophysiology
Professor, Medicine
Temple University
Philadelphia, PA

Akshay Desai, MD
Associate Director, Brigham Cardiovascular Consultants
Associate Professor, Medicine
Harvard Medical School
Boston, MA

Mark Drazner, MD, FHFS
Medical Director of the Heart Failure, LVAD, and Cardiac Transplantation Program
James M. Wooten Chair in Cardiology
Professor, Internal Medicine
University of Texas Southwestern Medical Center
Dallas, TX

Barry H. Greenberg, MD, FHFS
Distinguished Professor of Medicine
Director, Advanced Heart Failure Treatment Program
University of California, San Diego
La Jolla, CA

Anju Nohria, MD
Assistant Professor of Medicine, Harvard Medical School
Director, Brigham and Women’s Hospital/Dana Farber Cancer Institute
Boston, MA

Johnathan D. Rich, MD
Assistant Professor in Medicine-Cardiology
Northwestern University
Northwestern Memorial Hospital
Chicago, IL

Joseph G. Rogers, MD
Professor of Medicine
Interim Chief, Division of Cardiology
Vice Chair for Clinical Practice, Department of Internal Medicine
Duke University School of Medicine
Durham, NC
Clayton W. Yancy, MD, MSc, FHFSA
Vice-Dean, Diversity & Inclusion
Professor of Medicine
Professor, Medical Social Sciences
Chief, Cardiology Associate Director, Bluhm Cardiovascular Institute
Northwestern University, FSM & Northwestern Memorial Hospital
Chicago, IL

Disclosures: Presenters and Planners:

As a provider accredited by ACCME, HFSA must ensure balance, independence, objectivity and scientific rigor in its educational activities. Course Directors, planning committee members, and speakers are required to disclose all relevant financial relationships. Faculty will also disclose off-label or investigational uses of pharmaceuticals or devices discussed in their presentations. All potential conflicts have been resolved in accordance with ACCME guidelines for commercial support and content validation.

James C. Fang, MD, FACC, FAHA (Chair)
Nothing to disclose

Sean P. Pinney, MD (Chair)
Nothing to disclose

Kirkwood Adams, MD
Research: Novartis, Amgen, Roche, Otsuka, Cardiorentis
Consultant: Amgen, Relypsa, Merck

Allen S. Anderson, MD, FACC, FAHA
Research: St. Jude / Thoratec
Honoraria: Novartis, Amgen
Consultant: GE HealthCare

Barry A. Borlaug, MD
Employment: Mayo Clinic
Research: Aires Pharma, Inc., Amgen, Medtronic
Consultant: Merck and Co, Inc

Daniel Burkhoff, MD, PhD
Ownership Interest: PVLoops LLC (educational software)

Joshua M. Cooper, MD
Employment: Temple University
Honoraria: Biotronick, Boston Scientific, Medtronic, St. Jude
Consultant: Biotronick, Biosense

Akshay Desai, MD
Nothing to disclose
Mark Drazner, MD, FHFSA
Nothing to disclose

Barry H. Greenberg, MD, FHFSA
Nothing to disclose

Anju Nohria, MD
Research: Amgen (Pending)

Johnathan D. Rich, MD
Nothing to disclose

Joseph G. Rogers, MD
Nothing to disclose

Clyde W. Yancy, MD, MSc, FHFSA
No relevant relationships to disclose

Jaime Abreu, MBA (HFSA Staff, Planning Committee)
Nothing to disclose

**Method of Participation and CME Certificate:**
The information provided in this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. This product offers up to 19.5 hours of CME credit based on the number of hours you spend watching the sessions. To receive CME credit for this product, you must:

- Sign in or Register for the Product.
- Read the CME information including target audience, learning objectives, and faculty disclosures.
- Complete the Pre-Test by recording the best answer to each question. There is no scoring of the pre-test questions section.
- View the educational activity.
- Complete the post-test and evaluation questions by clicking on the CE Information tab within the session that you wish to evaluate and recording the best answer to each question. You must score 80% or higher on the combined session test, but you will have the opportunity to re-take questions that you missed until you score 80%.
- To receive your certificate, you must receive a passing score. After successfully completing the post-test and evaluation, your CME certificate will be generated and immediately available for print. Your credit will be archived and tallied.

**Medium or Combination of Media Used:**
The 2016 HFSA Board Review Course on Demand is available in these format offerings:

- Online access with downloadable MP3 files
- Mobile version for most mobile devices
Hardware/Software Requirements:
Please see below for the most current list of system requirements.

- Adobe Flash Plugin (Click on the link to install: http://get.adobe.com/flashplayer/)
- Supported Browsers: Internet Explorer 9 or higher, Firefox, Chrome
- Computer with speakers and/or headset
- High speed internet connection

Provider Contact Information:
For Customer Support, please contact: support@digitellinc.com or Toll Free: 877-796-1325

Heart Failure Society of America Contact Information:
Heart Failure Society of America, Inc.
6707 Democracy Blvd, Suite 925
Bethesda, MD 20817

Privacy Statement:
The Heart Failure Society of America (HFSA) respects the privacy of its members and website visitors. The HFSA website collects data only to better serve members and other users of our website.

Information Collected by HFSA:
Individual information, including contact information and demographics, is gathered from members, customers, education users, conference registrants and others. To gain access to members-only areas and personalized features on the website, users must join HFSA and provide individual information. Information submitted online may be used for other HFSA marketing uses, such as email and mail notifications of upcoming events that match the interests you provide us. Data are submitted voluntarily.

Whenever HFSA requests your personal information, to the extent that HFSA intends to use it in a manner not disclosed in this Privacy Policy, HFSA will try to explain to you its intended use, and to provide you with a choice to decline certain uses.

Disclosures to Third Parties:
HFSA will not sell or rent information gathered from website access to anyone except when:

- We have your consent to share the information;
- We need to share your information to provide the product or service you requested; or
- We need to send the information to companies working on behalf of HFSA to provide a product or service.
- When required to do so (i) by law, (ii) to comply with legal processes or governmental requests, (iii) to enforce our Terms and Conditions, or (iv) to protect the rights, property, or safety of HFSA, its users or the public.
- On occasion, HFSA may also provide limited data to third parties that offer related products and services. These limited data include names, job titles, companies and business addresses, but do not include business phone numbers or business fax. Users may request HFSA to refrain from disclosing the data it collects to third parties by contacting HFSA at info@hfsa.org or (301) 312-8635 to express their preferences if they determine later that they do not wish to have the information shared.
Companies that receive personal information from HFSA to execute the businesses of HFSA may use personal information only for that purpose.

**Credit Card Account Information:**
HFSA does not disclose credit card account information provided by its members and customers. When members and customers choose to pay using their credit cards, HFSA submits only the information needed to obtain payment to the appropriate clearinghouse. Credit card information is not saved nor maintained in any HFSA database and therefore cannot be used for any additional purpose other than the original purchase.

**Cookies:**
Like most websites, HFSA uses cookies to allow you to move more efficiently through our website. Cookies are small text files that allow HFSA to recognize repeat users and facilitate their access to and use of the site. Cookies do not collect personally identifying information. HFSA uses this information only for purposes of planning and tracking, as well as assessing the technical function of our site. By understanding how our site is accessed, we can continually improve it to respond to user interests. However, we cannot control the use of cookies by advertisers or third parties hosting data on our behalf. If you do not want information collected using cookies, there is a simple procedure in most browsers that allows you to deny or accept the cookie feature.

**Links to Non-HFSA Sites:**
Please note that the HFSA site contains links to other websites. HFSA is not responsible for the privacy practices, privacy statements, or content regarding these other sites.

**ABIM ID:**
Click on the link to lookup your ABIM ID [http://www.abim.org/online/findcand.aspx](http://www.abim.org/online/findcand.aspx)